表紙
市場調查報告書
商品編碼
1029930

全球Hunter氏症候群治療市場 - 到 2028 年的行業趨勢和預測

Global Hunter Syndrome Treatment Market- Industry Trends and Forecast to 2028

出版日期: | 出版商: Data Bridge Market Research Private Limited | 英文 321 Pages | 商品交期: 3-5個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

預計全球Hunter氏症候群治療市場在 2021 年至 2028 年間的複合年增長率將達到 8.1%。

本報告調查和分析了全球Hunter氏症候群治療市場,包括新治療、監管指南 (MPS II)、流行病、促進因素、抑制因素、市場機會、COVID-19 影響和嚴重程度。按類型、併發症、按最終用戶、按分銷渠道、按地區、市場信息、企業情況、SWOT 分析、企業概況。

目錄

第 1 章介紹

第 2 章市場細分

第 3 章執行摘要

第 4 章重要考慮事項

第 5 章 Hunter 綜合徵的新療法

  • 處理:DNL310
  • 處理:JR141
  • 處理:TAK-609/SHP609/HGT-2310
  • 處理:RGX-121
  • 處理:SB-913
  • 處理:AVR-RD-05
  • 治療:ODIPARCIL
  • 處理:AGT-181
  • 處理:EGT-301

Hunter氏症候群(MPS II)第 6 章監管指南

  • Hunter氏症候群:美國監管框架
  • Hunter氏症候群:歐洲監管框架
  • Hunter氏症候群:亞太地區監管框架

第 7 章流行病學

第 8 章市場概覽

  • 促進因素
    • Hunter氏症候群患病率增加
    • 越來越多地採用基因療法
    • 加大政府工作力度
    • 增加公共和私營部門的資金
    • 技術進步
  • 抑制因素
    • 目前治療的副作用
    • 政府對 MPSII 治療開發的嚴格規定
    • 人們對Hunter氏症候群的存在缺乏認識
    • 與 MPS II 治療相關的高成本
  • 市場機會
    • 對疾病特異性治療的高需求
    • 大公司合作、併購
    • 新途徑藥物的存在
  • 挑戰
    • 當前的治療限制
  • 不當的兌換政策

第 9 章全球Hunter氏症候群治療市場:COVID-19 的影響

  • 對價格的影響
  • 對需求的影響
  • 對供應鏈的影響
  • 製造商的戰略決策
  • 結論

第 10 章全球Hunter氏症候群治療市場:按嚴重程度

  • 概述
  • 中度至重度
  • 輕度至中度

第 11 章全球Hunter氏症候群治療市場:按類型

  • 概述
  • □替代療法
    • ELAPRASE + TAK-609
    • 漢特□
    • IZCARGO
  • 幹細胞移植
    • 臍帶移植
    • 骨髓移植
  • 手術治療
    • 心臟瓣膜置換術
    • 氣管切開術
    • 氣道正壓裝置
    • 關節攣縮
    • 腹疝手術
    • 其他
  • 其他

第 12 章全球Hunter氏症候群治療市場:按併發症

  • 概述
  • 呼吸系統疾病
  • 神經紊亂
  • 心血管
  • 肌肉骨骼
  • 胃腸道疾病
  • 眼科
  • 聽力學
  • 牙科
  • 其他

第 13 章全球Hunter氏症候群治療市場:按最終用戶

  • 概述
  • 醫院
  • 診所
  • 醫療保健
  • 其他

第 14 章全球Hunter氏症候群治療市場:按分銷渠道

  • 概述
  • 醫院藥房
  • 零售藥店
  • 網上藥店
  • 其他

第 15 章全球Hunter氏症候群治療市場:按地區

  • 概述
  • 亞太地區
    • 日本
    • 韓國
    • 中國
    • 印度
    • 澳大利亞
    • 新加坡
    • 馬來西亞
    • 泰國
    • 印度尼西亞
    • 菲律賓
    • 越南
    • 其他亞太地區
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 意大利
    • 西班牙
    • 荷蘭
    • 俄羅斯
    • 瑞士
    • 土耳其
    • 奧地利
    • 挪威
    • 匈牙利
    • 立陶宛
    • 波蘭
    • 愛爾蘭
    • 其他歐洲
  • 中東/非洲
    • 南非
    • 沙特阿拉伯
    • 阿拉伯聯合酋長國
    • 埃及
    • 以色列
    • 科威特
    • 其他中東和非洲
  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 秘魯
    • 其他南美洲

第 16 章全球Hunter氏症候群治療市場:企業狀況

  • 公司股票分析:世界
  • 公司份額分析:北美
  • 公司份額分析:歐洲
  • 企業股票分析:亞太地區

第 17 章SWOT分析

第 18 章公司簡介

  • TAKEDA PHARMACEUTICAL COMPANY LIMITED
  • GREEN CROSS CORP.
  • ABBOTT
  • AVROBIO, INC.
  • BD
  • CANBRIDGE LIFE SCIENCES LTD.
  • DENALI THERAPEUTICS
  • HOMOLOGY MEDICINES, INC.
  • INVENTIVA
  • JASPER THERAPEUTICS, INC.
  • JCR PHARMACEUTICALS CO., LTD.
  • JOHNSON & JOHNSONS SERVICES, INC.
  • MEDTRONIC
  • NOVARTIS AG
  • ON-X LIFE TECHNOLOGIES(A SUBSIDIARY OF CRYOLIFE, INC.)
  • PFIZER INC.
  • REGENXBIO INC.
  • SANGAMO THERAPEUTICS
  • STRYKER
  • UCB S.A.

第 19 章問卷

第 20 章相關報導

目錄

Global hunter syndrome treatment market is projected to register a healthy CAGR of 8.1% in the forecast period of 2021 to 2028. The new market report contains data for the historic year 2019, the base year of calculation is 2020 and the forecast period is 2021 to 2028.

Market Segmentation:

Global Hunter Syndrome Treatment Market, By Severity (Mild to Moderate, Moderate to Severe), Type (Enzyme Replacement Therapy (ERT), Stem Cell Transplant, Surgical Treatment, Others), Complications (Respiratory Disorders, Neurological Disorders, Gastrointestinal Disorders, Cardiovascular, Ophthalmic, Audiologic, Dental, Musculoskeletal, Others), End User (Hospitals, Clinics, Home Healthcare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others), Country (U.S., Canada, Mexico, Germany, U.K., France, Italy, Spain, Netherlands, Russia, Switzerland, Belgium, Turkey, Austria, Norway, Hungary, Lithuania, Ireland, Poland, Rest of Europe, Japan, China, Australia, India, South Korea, Singapore, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Rest of Asia-Pacific, Brazil, Argentina, Peru, Rest of South America, Saudi Arabia, South Africa, UAE, Israel, Kuwait, Egypt and Rest of Middle East and Africa) Industry Trends and Forecast to 2028

Some of the major factors contributing to the growth of global hunter syndrome treatment market are:

  • Increasing prevalence of hunter syndrome
  • Rising adoption of gene therapy
  • Increasing government initiatives
  • Increasing fund by public and private organizations

Market Players:

The key market players for global hunter syndrome treatment market are listed below:

  • Pfizer Inc.
  • Takeda Pharmaceutical Company Limited
  • Medtronic
  • Abbott
  • On-X Life Technologies (a subsidiary of CryoLife, Inc.)
  • BD
  • Medical Device Business Services Inc.
  • Stryker
  • Homology Medicines Inc.
  • UCB S.A
  • Novartis AG
  • JCR Pharmaceutical Co.ltd
  • Sangamo Therapeutics
  • AVROBIO Inc.
  • REGENXBIO Inc
  • CANbridge Life Sciences Ltd.
  • Denali Therapeutics
  • Jasper Therapeutics Inc.
  • Green Cross Corp.
  • Inventiva
  • Johnson & Johnson Services, Inc.

TABLE OF CONTENTS

1 INTRODUCTION 32

  • 1.1 OBJECTIVES OF THE STUDY 32
  • 1.2 MARKET DEFINITION 32
  • 1.3 OVERVIEW OF GLOBAL HUNTER SYNDROME TREATMENT MARKET 32
  • 1.4 LIMITATIONS 34
  • 1.5 MARKETS COVERED 34

2 MARKET SEGMENTATION 37

  • 2.1 MARKETS COVERED 37
  • 2.2 GEOGRAPHICAL SCOPE 38
  • 2.3 YEARS CONSIDERED FOR THE STUDY 39
  • 2.4 CURRENCY AND PRICING 39
  • 2.5 DBMR TRIPOD DATA VALIDATION MODEL 40
  • 2.6 MULTIVARIATE MODELLING 43
  • 2.7 SEVERITY LIFELINE CURVE 44
  • 2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 45
  • 2.9 DBMR MARKET POSITION GRID 46
  • 2.10 MARKET END USER COVERAGE GRID 47
  • 2.11 VENDOR SHARE ANALYSIS 48
  • 2.12 SECONDARY SOURCES 49
  • 2.13 ASSUMPTIONS 49

3 EXECUTIVE SUMMARY 51

4 PREMIUM INSIGHTS 54

5 EMERGING TREATMENTS FOR HUNTER SYNDROME 57

  • 5.1 TREATMENT: DNL310 57
  • 5.2 TREATMENT: JR141 57
  • 5.3 TREATMENT: TAK-609/SHP609/HGT-2310 57
  • 5.4 TREATMENT: RGX-121 57
  • 5.5 TREATMENT: SB-913 58
  • 5.6 TREATMENT: AVR-RD-05 58
  • 5.7 TREATMENT: ODIPARCIL 58
  • 5.8 TREATMENT: AGT-181 58
  • 5.9 TREATMENT: EGT-301 59

6 REGULATORY GUIDELINES FOR HUNTER SYNDROME (MPS II) 60

  • 6.1 U.S REGULATORY FRAMEWORK FOR HUNTER SYNDROME 60
  • 6.2 EUROPE REGULATORY FRAMEWORK FOR HUNTER SYNDROME 60
  • 6.3 ASIA-PACIFIC REGULATORY FRAMEWORK FOR HUNTER SYNDROME 61

7 EPIDEMIOLOGY 63

8 MARKET OVERVIEW 64

  • 8.1 DRIVERS 66
    • 8.1.1 INCREASING PREVALENCE OF HUNTER SYNDROME 66
    • 8.1.2 RISING ADOPTION OF GENE THERAPY 66
    • 8.1.3 INCREASING GOVERNMENT INITIATIVES 67
    • 8.1.4 INCREASING FUND BY PUBLIC AND PRIVATE ORGANISATIONS 67
    • 8.1.5 TECHNOLOGICAL ADVANCEMENTS 67
  • 8.2 RESTRAINTS 68
    • 8.2.1 ADVERSE EFFECTS OF CURRENT TREATMENTS 68
    • 8.2.2 STRINGENT GOVERNMENT REGULATIONS FOR MPS II TREATMENT DEVELOPMENT 68
    • 8.2.3 UNAWARENESS AMONG PEOPLE OF THE EXISTENCE OF HUNTER SYNDROME 69
    • 8.2.4 HIGH COST ASSOCIATED WITH TREATMENT OF MPS II 69
  • 8.3 OPPORTUNITIES 69
    • 8.3.1 HIGH DEMAND OF DISEASE-SPECIFIC TREATMENT 69
    • 8.3.2 RISING COLLABORATIONS, AND MERGERS & ACQUISITIONS AMONG THE MARKET PLAYERS 70
    • 8.3.3 PRESENCE OF NOVEL PIPELINE DRUGS 70
  • 8.4 CHALLENGES 71
    • 8.4.1 LIMITATIONS OF CURRENT TREATMENT 71
  • 8.5 IMPROPER REIMBURSEMENT POLICIES 71

9 IMPACT OF COVID-19 ON THE GLOBAL HUNTER SYNDROME TREATMENT MARKET 72

  • 9.1 IMPACT ON PRICE 72
  • 9.2 IMPACT ON DEMAND 73
  • 9.3 IMPACT ON SUPPLY CHAIN 73
  • 9.4 STRATEGIC DECISIONS FOR MANUFACTURERS 74
  • 9.5 CONCLUSION 74

10 GLOBAL HUNTER SYNDROME TREATMENT MARKET, BY SEVERITY 76

  • 10.1 OVERVIEW 77
  • 10.2 MODERATE TO SEVERE 78
  • 10.3 MILD TO MODERATE 78

11 GLOBAL HUNTER SYNDROME TREATMENT MARKET, BY TYPE 79

  • 11.1 OVERVIEW 80
  • 11.2 ENZYME REPLACEMENT THERAPY 81
    • 11.2.1 ELAPRASE + TAK-609 82
    • 11.2.2 HUNTERASE 82
    • 11.2.3 IZCARGO 82
  • 11.3 STEM CELL TRANSPLANT 82
    • 11.3.1 UMBILICAL CORD TRANSPLANT 83
    • 11.3.2 BONE MARROW TRANSPLANT 83
  • 11.4 SURGICAL TREATMENT 83
    • 11.4.1 CARDIAC VALVE REPLACEMENT SURGERY 84
    • 11.4.2 TRACHEOSTOMY 84
    • 11.4.3 POSITIVE AIRWAY PRESSURE DEVICES 84
    • 11.4.4 JOINT CONTRACTURES 84
    • 11.4.5 ABDOMINAL HERNIA SURGERY 84
    • 11.4.6 OTHERS 84
  • 11.5 OTHERS 84

12 GLOBAL HUNTER SYNDROME TREATMENT MARKET, BY COMPLICATIONS 85

  • 12.1 OVERVIEW 86
  • 12.2 RESPIRATORY DISORDERS 87
  • 12.3 NEUROLOGICAL DISORDERS 88
  • 12.4 CARDIOVASCULAR 88
  • 12.5 MUSCULOSKELETAL 89
  • 12.6 GASTROINTESTINAL DISORDERS 89
  • 12.7 OPHTHALMIC 90
  • 12.8 AUDIOLOGIC 90
  • 12.9 DENTAL 91
  • 12.10 OTHERS 91

13 GLOBAL HUNTER SYNDROME TREATMENT MARKET, BY END USER 92

  • 13.1 OVERVIEW 93
  • 13.2 HOSPITALS 94
  • 13.3 CLINICS 94
  • 13.4 HOME HEALTHCARE 95
  • 13.5 OTHERS 95

14 GLOBAL HUNTER SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL 96

  • 14.1 OVERVIEW 97
  • 14.2 HOSPITAL PHARMACY 98
  • 14.3 RETAIL PHARMACY 98
  • 14.4 ONLINE PHARMACY 99
  • 14.5 OTHERS 99

15 GLOBAL HUNTER SYNDROME TREATMENT MARKET, BY REGION 100

  • 15.1 OVERVIEW 101
  • 15.2 ASIA-PACIFIC 106
    • 15.2.1 JAPAN 112
    • 15.2.2 SOUTH KOREA 115
    • 15.2.3 CHINA 118
    • 15.2.4 INDIA 121
    • 15.2.5 AUSTRALIA 124
    • 15.2.6 SINGAPORE 127
    • 15.2.7 MALAYSIA 130
    • 15.2.8 THAILAND 133
    • 15.2.9 INDONESIA 136
    • 15.2.10 PHILIPPINES 139
    • 15.2.11 VIETNAM 142
    • 15.2.12 REST OF ASIA-PACIFIC 145
  • 15.3 EUROPE 146
    • 15.3.1 GERMANY 153
    • 15.3.2 FRANCE 156
    • 15.3.3 U.K. 159
    • 15.3.4 ITALY 162
    • 15.3.5 SPAIN 165
    • 15.3.6 NETHERLANDS 168
    • 15.3.7 RUSSIA 171
    • 15.3.8 SWITZERLAND 174
    • 15.3.9 TURKEY 177
    • 15.3.10 AUSTRIA 180
    • 15.3.11 NORWAY 183
    • 15.3.12 HUNGARY 186
    • 15.3.13 LITHUANIA 189
    • 15.3.14 POLAND 192
    • 15.3.15 IRELAND 195
    • 15.3.16 REST OF EUROPE 198
  • 15.4 MIDDLE EAST & AFRICA 199
    • 15.4.1 SOUTH AFRICA 205
    • 15.4.2 SAUDI ARABIA 208
    • 15.4.3 U.A.E. 211
    • 15.4.4 EGYPT 214
    • 15.4.5 ISRAEL 217
    • 15.4.6 KUWAIT 220
    • 15.4.7 REST OF MIDDLE EAST & AFRICA 223
  • 15.5 NORTH AMERICA 224
    • 15.5.1 U.S. 230
    • 15.5.2 CANADA 233
    • 15.5.3 MEXICO 236
  • 15.6 SOUTH AMERICA 239
    • 15.6.1 BRAZIL 245
    • 15.6.2 ARGENTINA 248
    • 15.6.3 PERU 251
    • 15.6.4 REST OF SOUTH AMERICA 254

16 GLOBAL HUNTER SYNDROME TREATMENT MARKET: COMPANY LANDSCAPE 255

  • 16.1 COMPANY SHARE ANALYSIS: GLOBAL 255
  • 16.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 256
  • 16.3 COMPANY SHARE ANALYSIS: EUROPE 257
  • 16.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 258

17 SWOT ANALYSIS 259

18 COMPANY PROFILE 260

  • 18.1 TAKEDA PHARMACEUTICAL COMPANY LIMITED 260
    • 18.1.1 COMPANY SNAPSHOT 260
    • 18.1.2 REVENUE ANALYSIS 261
    • 18.1.3 COMPANY SHARE ANALYSIS 261
    • 18.1.4 PRODUCT PORTFOLIO 261
    • 18.1.5 RECENT DEVELOPMENTS 262
  • 18.2 GREEN CROSS CORP. 264
    • 18.2.1 COMPANY SNAPSHOT 264
    • 18.2.2 REVENUE ANALYSIS 264
    • 18.2.3 COMPANY SHARE ANALYSIS 265
    • 18.2.4 PRODUCT PORTFOLIO 265
    • 18.2.5 RECENT DEVELOPMENT 265
  • 18.3 ABBOTT 266
    • 18.3.1 COMPANY SNAPSHOT 266
    • 18.3.2 REVENUE ANALYSIS 266
    • 18.3.3 PRODUCT PORTFOLIO 267
    • 18.3.4 RECENT DEVELOPMENTS 267
  • 18.4 AVROBIO, INC. 270
    • 18.4.1 COMPANY SNAPSHOT 270
    • 18.4.2 PRODUCT PORTFOLIO 270
    • 18.4.3 RECENT DEVELOPMENTS 270
  • 18.5 BD 273
    • 18.5.1 COMPANY SNAPSHOT 273
    • 18.5.2 REVENUE ANALYSIS 273
    • 18.5.3 PRODUCT PORTFOLIO 274
    • 18.5.4 RECENT DEVELOPMENT 274
  • 18.6 CANBRIDGE LIFE SCIENCES LTD. 275
    • 18.6.1 COMPANY SNAPSHOT 275
    • 18.6.2 PRODUCT PORTFOLIO 276
    • 18.6.3 RECENT DEVELOPMENTS 276
  • 18.7 DENALI THERAPEUTICS 277
    • 18.7.1 COMPANY SNAPSHOT 277
    • 18.7.2 REVENUE ANALYSIS 277
    • 18.7.3 PRODUCT PORTFOLIO 278
    • 18.7.4 RECENT DEVELOPMENTS 278
  • 18.8 HOMOLOGY MEDICINES, INC. 279
    • 18.8.1 COMPANY SNAPSHOT 279
    • 18.8.2 REVENUE ANALYSIS 279
    • 18.8.3 TECHNOLOGY PORTFOLIO 280
    • 18.8.4 RECENT DEVELOPMENTS 280
  • 18.9 INVENTIVA 281
    • 18.9.1 COMPANY SNAPSHOT 281
    • 18.9.2 REVENUE ANALYSIS 281
    • 18.9.3 PRODUCT PORTFOLIO 282
    • 18.9.4 RECENT DEVELOPMENTS 282
  • 18.10 JASPER THERAPEUTICS, INC. 284
    • 18.10.1 COMPANY SNAPSHOT 284
    • 18.10.2 PRODUCT PORTFOLIO 284
    • 18.10.3 RECENT DEVELOPMENT 284
  • 18.11 JCR PHARMACEUTICALS CO., LTD. 285
    • 18.11.1 COMPANY SNAPSHOT 285
    • 18.11.2 REVENUE ANALYSIS 285
    • 18.11.3 PRODUCT PORTFOLIO 286
    • 18.11.4 RECENT DEVELOPMENTS 286
  • 18.12 JOHNSON & JOHNSONS SERVICES, INC. 288
    • 18.12.1 COMPANY SNAPSHOT 288
    • 18.12.2 REVENUE ANALYSIS 288
    • 18.12.3 PRODUCT PORTFOLIO 289
    • 18.12.4 RECENT DEVELOPMENTS 289
  • 18.13 MEDTRONIC 290
    • 18.13.1 COMPANY SNAPSHOT 290
    • 18.13.2 REVENUE ANALYSIS 291
    • 18.13.3 PRODUCT PORTFOLIO 291
    • 18.13.4 RECENT DEVELOPMENTS 292
  • 18.14 NOVARTIS AG 295
    • 18.14.1 COMPANY SNAPSHOT 295
    • 18.14.2 REVENUE ANALYSIS 295
    • 18.14.3 PRODUCT PORTFOLIO 296
    • 18.14.4 RECENT DEVELOPMENTS 296
  • 18.15 ON-X LIFE TECHNOLOGIES (A SUBSIDIARY OF CRYOLIFE, INC.) 299
    • 18.15.1 COMPANY SNAPSHOT 299
    • 18.15.2 REVENUE ANALYSIS 299
    • 18.15.3 PRODUCT PORTFOLIO 300
    • 18.15.4 RECENT DEVELOPMENTS 300
  • 18.16 PFIZER INC. 302
    • 18.16.1 COMPANY SNAPSHOT 302
    • 18.16.2 REVENUE ANALYSIS 302
    • 18.16.3 PRODUCT PORTFOLIO 303
    • 18.16.4 RECENT DEVELOPMENTS 303
  • 18.17 REGENXBIO INC. 305
    • 18.17.1 COMPANY SNAPSHOT 305
    • 18.17.2 REVENUE ANALYSIS 305
    • 18.17.3 PRODUCT PORTFOLIO 306
    • 18.17.4 RECENT DEVELOPMENTS 307
  • 18.18 SANGAMO THERAPEUTICS 308
    • 18.18.1 COMPANY SNAPSHOT 308
    • 18.18.2 REVENUE ANALYSIS 308
    • 18.18.3 PRODUCT PORTFOLIO 309
    • 18.18.4 RECENT DEVELOPMENT 309
  • 18.19 STRYKER 310
    • 18.19.1 COMPANY SNAPSHOT 310
    • 18.19.2 REVENUE ANALYSIS 310
    • 18.19.3 PRODUCT PORTFOLIO 311
    • 18.19.4 RECENT DEVELOPMENTS 312
  • 18.20 UCB S.A. 313
    • 18.20.1 COMPANY SNAPSHOT 313
    • 18.20.2 REVENUE ANALYSIS 313
    • 18.20.3 PRODUCT PORTFOLIO 314
    • 18.20.4 RECENT DEVELOPMENTS 315

19 QUESTIONNAIRE 317

20 RELATED REPORTS 321

LIST OF TABLES

  • TABLE 1 GLOBAL HUNTER SYNDROME TREATMENT MARKET, BY SEVERITY, 2019-2028 (USD MILLION) 78
  • TABLE 2 GLOBAL MODERATE TO SEVERE IN HUNTER SYNDROME TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION) 78
  • TABLE 3 GLOBAL MILD TO MODERATE IN GLOBAL HUNTER SYNDROME TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION) 78
  • TABLE 4 GLOBAL HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION) 81
  • TABLE 5 GLOBAL ENZYME REPLACEMENT THERAPY (ERT) IN HUNTER SYNDROME TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION) 81
  • TABLE 6 GLOBAL ENZYME REPLACEMENT THERAPY (ERT) IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION) 81
  • TABLE 7 GLOBAL STEM CELL TRANSPLANT IN HUNTER SYNDROME TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION) 82
  • TABLE 8 GLOBAL STEM CELL TRANSPLANT IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION) 82
  • TABLE 9 GLOBAL SURGICAL TREATMENT IN HUNTER SYNDROME TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION) 83
  • TABLE 10 GLOBAL SURGICAL TREATMENT IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION) 83
  • TABLE 11 GLOBAL OTHERS IN HUNTER SYNDROME TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION) 84
  • TABLE 12 GLOBAL HUNTER SYNDROME TREATMENT MARKET, BY COMPLICATIONS, 2019-2028 (USD MILLION) 87
  • TABLE 13 GLOBAL RESPIRATORY DISORDERS IN HUNTER SYNDROME TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION) 87
  • TABLE 14 GLOBAL NEUROLOGICAL DISORDERS IN HUNTER SYNDROME TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION) 88
  • TABLE 15 GLOBAL CARDIOVASCULAR IN HUNTER SYNDROME TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION) 88
  • TABLE 16 GLOBAL MUSCULOSKELETAL IN HUNTER SYNDROME TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION) 89
  • TABLE 17 GLOBAL GASTROINTESTINAL DISORDERS IN HUNTER SYNDROME TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION) 89
  • TABLE 18 GLOBAL OPHTHALMIC IN HUNTER SYNDROME TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION) 90
  • TABLE 19 GLOBAL AUDIOLOGIC IN HUNTER SYNDROME TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION) 90
  • TABLE 20 GLOBAL DENTAL IN HUNTER SYNDROME TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION) 91
  • TABLE 21 GLOBAL OTHERS IN HUNTER SYNDROME TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION) 91
  • TABLE 22 GLOBAL HUNTER SYNDROME TREATMENT MARKET: BY END USER, 2020 94
  • TABLE 23 GLOBAL HOSPITALS IN HUNTER SYNDROME TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION) 94
  • TABLE 24 GLOBAL CLINICS IN HUNTER SYNDROME TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION) 94
  • TABLE 25 GLOBAL HOME HEALTHCARE IN HUNTER SYNDROME TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION) 95
  • TABLE 26 GLOBAL OTHERS IN HUNTER SYNDROME TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION) 95
  • TABLE 27 GLOBAL HUNTER SYNDROME TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2020 98
  • TABLE 28 GLOBAL HOSPITAL PHARMACY IN HUNTER SYNDROME TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION) 98
  • TABLE 29 GLOBAL RETAIL PHARMACY IN HUNTER SYNDROME MARKET, BY REGION, 2019-2028 (USD MILLION) 98
  • TABLE 30 GLOBAL ONLINE PHARMACY IN HUNTER SYNDROME TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION) 99
  • TABLE 31 GLOBAL OTHERS IN HUNTER SYNDROME TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION) 99
  • TABLE 32 GLOBAL HUNTER SYNDROME TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION) 105
  • TABLE 33 ASIA-PACIFIC HUNTER SYNDROME TREATMENT MARKET, BY COUNTRY, 2019-2028 (USD MILLION) 109
  • TABLE 34 ASIA-PACIFIC HUNTER SYNDROME TREATMENT MARKET, BY SEVERITY, 2019-2028 (USD MILLION) 109
  • TABLE 35 ASIA-PACIFIC HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION) 109
  • TABLE 36 ASIA-PACIFIC ENZYME REPLACEMENT THERAPY (ERT) IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION) 110
  • TABLE 37 ASIA-PACIFIC STEM CELL TRANSPLANT IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION) 110
  • TABLE 38 ASIA-PACIFIC SURGICAL TREATMENT IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION) 110
  • TABLE 39 ASIA-PACIFIC HUNTER SYNDROME TREATMENT MARKET, BY COMPLICATIONS, 2019-2028 (USD MILLION) 111
  • TABLE 40 ASIA-PACIFIC HUNTER SYNDROME TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION) 111
  • TABLE 41 ASIA-PACIFIC HUNTER SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION) 111
  • TABLE 42 JAPAN HUNTER SYNDROME TREATMENT MARKET, BY SEVERITY, 2019-2028 (USD MILLION) 112
  • TABLE 43 JAPAN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION) 112
  • TABLE 44 JAPAN ENZYME REPLACEMENT THERAPY (ERT) IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION) 112
  • TABLE 45 JAPAN STEM CELL TRANSPLANT IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION) 112
  • TABLE 46 JAPAN SURGICAL TREATMENT IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION) 113
  • TABLE 47 JAPAN HUNTER SYNDROME TREATMENT MARKET, BY COMPLICATIONS, 2019-2028 (USD MILLION) 113
  • TABLE 48 JAPAN HUNTER SYNDROME TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION) 113
  • TABLE 49 JAPAN HUNTER SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION) 114
  • TABLE 50 SOUTH KOREA HUNTER SYNDROME TREATMENT MARKET, BY SEVERITY, 2019-2028 (USD MILLION) 115
  • TABLE 51 SOUTH KOREA HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION) 115
  • TABLE 52 SOUTH KOREA ENZYME REPLACEMENT THERAPY (ERT) IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION) 115
  • TABLE 53 SOUTH KOREA STEM CELL TRANSPLANT IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION) 115
  • TABLE 54 SOUTH KOREA SURGICAL TREATMENT IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION) 116
  • TABLE 55 SOUTH KOREA HUNTER SYNDROME TREATMENT MARKET, BY COMPLICATIONS, 2019-2028 (USD MILLION) 116
  • TABLE 56 SOUTH KOREA HUNTER SYNDROME TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION) 116
  • TABLE 57 SOUTH KOREA HUNTER SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION) 117
  • TABLE 58 CHINA HUNTER SYNDROME TREATMENT MARKET, BY SEVERITY, 2019-2028 (USD MILLION) 118
  • TABLE 59 CHINA HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION) 118
  • TABLE 60 CHINA ENZYME REPLACEMENT THERAPY (ERT) IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION) 118
  • TABLE 61 CHINA STEM CELL TRANSPLANT IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION) 118
  • TABLE 62 CHINA SURGICAL TREATMENT IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION) 119
  • TABLE 63 CHINA HUNTER SYNDROME TREATMENT MARKET, BY COMPLICATIONS, 2019-2028 (USD MILLION) 119
  • TABLE 64 CHINA HUNTER SYNDROME TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION) 119
  • TABLE 65 CHINA HUNTER SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION) 120
  • TABLE 66 INDIA HUNTER SYNDROME TREATMENT MARKET, BY SEVERITY, 2019-2028 (USD MILLION) 121
  • TABLE 67 INDIA HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION) 121
  • TABLE 68 INDIA ENZYME REPLACEMENT THERAPY (ERT) IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION) 121
  • TABLE 69 INDIA STEM CELL TRANSPLANT IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION) 121
  • TABLE 70 INDIA SURGICAL TREATMENT IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION) 122
  • TABLE 71 INDIA HUNTER SYNDROME TREATMENT MARKET, BY COMPLICATIONS, 2019-2028 (USD MILLION) 122
  • TABLE 72 INDIA HUNTER SYNDROME TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION) 122
  • TABLE 73 INDIA HUNTER SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION) 123
  • TABLE 74 AUSTRALIA HUNTER SYNDROME TREATMENT MARKET, BY SEVERITY, 2019-2028 (USD MILLION) 124
  • TABLE 75 AUSTRALIA HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION) 124
  • TABLE 76 AUSTRALIA ENZYME REPLACEMENT THERAPY (ERT) IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION) 124
  • TABLE 77 AUSTRALIA STEM CELL TRANSPLANT IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION) 124
  • TABLE 78 AUSTRALIA SURGICAL TREATMENT IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION) 125
  • TABLE 79 AUSTRALIA HUNTER SYNDROME TREATMENT MARKET, BY COMPLICATIONS, 2019-2028 (USD MILLION) 125
  • TABLE 80 AUSTRALIA HUNTER SYNDROME TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION) 125
  • TABLE 81 AUSTRALIA HUNTER SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION) 126
  • TABLE 82 SINGAPORE HUNTER SYNDROME TREATMENT MARKET, BY SEVERITY, 2019-2028 (USD MILLION) 127
  • TABLE 83 SINGAPORE HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION) 127
  • TABLE 84 SINGAPORE ENZYME REPLACEMENT THERAPY (ERT) IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION) 127
  • TABLE 85 SINGAPORE STEM CELL TRANSPLANT IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION) 127
  • TABLE 86 SINGAPORE SURGICAL TREATMENT IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION) 128
  • TABLE 87 SINGAPORE HUNTER SYNDROME TREATMENT MARKET, BY COMPLICATIONS, 2019-2028 (USD MILLION) 128
  • TABLE 88 SINGAPORE HUNTER SYNDROME TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION) 128
  • TABLE 89 SINGAPORE HUNTER SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION) 129
  • TABLE 90 MALAYSIA HUNTER SYNDROME TREATMENT MARKET, BY SEVERITY, 2019-2028 (USD MILLION) 130
  • TABLE 91 MALAYSIA HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION) 130
  • TABLE 92 MALAYSIA ENZYME REPLACEMENT THERAPY (ERT) IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION) 130
  • TABLE 93 MALAYSIA STEM CELL TRANSPLANT IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION) 130
  • TABLE 94 MALAYSIA SURGICAL TREATMENT IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION) 131
  • TABLE 95 MALAYSIA HUNTER SYNDROME TREATMENT MARKET, BY COMPLICATIONS, 2019-2028 (USD MILLION) 131
  • TABLE 96 MALAYSIA HUNTER SYNDROME TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION) 131
  • TABLE 97 MALAYSIA HUNTER SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION) 132
  • TABLE 98 THAILAND HUNTER SYNDROME TREATMENT MARKET, BY SEVERITY, 2019-2028 (USD MILLION) 133
  • TABLE 99 THAILAND HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION) 133
  • TABLE 100 THAILAND ENZYME REPLACEMENT THERAPY (ERT) IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION) 133
  • TABLE 101 THAILAND STEM CELL TRANSPLANT IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION) 133
  • TABLE 102 THAILAND SURGICAL TREATMENT IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION) 133
  • TABLE 103 THAILAND HUNTER SYNDROME TREATMENT MARKET, BY COMPLICATIONS, 2019-2028 (USD MILLION) 134
  • TABLE 104 THAILAND HUNTER SYNDROME TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION) 134
  • TABLE 105 THAILAND HUNTER SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION) 134
  • TABLE 106 INDONESIA HUNTER SYNDROME TREATMENT MARKET, BY SEVERITY, 2019-2028 (USD MILLION) 136
  • TABLE 107 INDONESIA HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION) 136
  • TABLE 108 INDONESIA ENZYME REPLACEMENT THERAPY (ERT) IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION) 136
  • TABLE 109 INDONESIA STEM CELL TRANSPLANT IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION) 136
  • TABLE 110 INDONESIA SURGICAL TREATMENT IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION) 137
  • TABLE 111 INDONESIA HUNTER SYNDROME TREATMENT MARKET, BY COMPLICATIONS, 2019-2028 (USD MILLION) 137
  • TABLE 112 INDONESIA HUNTER SYNDROME TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION) 137
  • TABLE 113 INDONESIA HUNTER SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION) 138
  • TABLE 114 PHILIPPINES HUNTER SYNDROME TREATMENT MARKET, BY SEVERITY, 2019-2028 (USD MILLION) 139
  • TABLE 115 PHILIPPINES HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION) 139
  • TABLE 116 PHILIPPINES ENZYME REPLACEMENT THERAPY (ERT) IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION) 139
  • TABLE 117 PHILIPPINES STEM CELL TRANSPLANT IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION) 139
  • TABLE 118 PHILIPPINES SURGICAL TREATMENT IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION) 140
  • TABLE 119 PHILIPPINES HUNTER SYNDROME TREATMENT MARKET, BY COMPLICATIONS, 2019-2028 (USD MILLION) 140
  • TABLE 120 PHILIPPINES HUNTER SYNDROME TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION) 140
  • TABLE 121 PHILIPPINES HUNTER SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION) 141
  • TABLE 122 VIETNAM HUNTER SYNDROME TREATMENT MARKET, BY SEVERITY, 2019-2028 (USD MILLION) 142
  • TABLE 123 VIETNAM HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION) 142
  • TABLE 124 VIETNAM ENZYME REPLACEMENT THERAPY (ERT) IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION) 142
  • TABLE 125 VIETNAM STEM CELL TRANSPLANT IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION) 142
  • TABLE 126 VIETNAM SURGICAL TREATMENT IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION) 143
  • TABLE 127 VIETNAM HUNTER SYNDROME TREATMENT MARKET, BY COMPLICATIONS, 2019-2028 (USD MILLION) 143
  • TABLE 128 VIETNAM HUNTER SYNDROME TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION) 143
  • TABLE 129 VIETNAM HUNTER SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION) 144
  • TABLE 130 REST OF ASIA-PACIFIC HUNTER SYNDROME TREATMENT MARKET, BY SEVERITY, 2019-2028 (USD MILLION) 145
  • TABLE 131 EUROPE HUNTER SYNDROME TREATMENT MARKET, BY COUNTRY, 2019-2028 (USD MILLION) 150
  • TABLE 132 EUROPE HUNTER SYNDROME TREATMENT MARKET, BY SEVERITY, 2019-2028 (USD MILLION) 150
  • TABLE 133 EUROPE HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION) 150
  • TABLE 134 EUROPE ENZYME REPLACEMENT THERAPY (ERT) IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION) 151
  • TABLE 135 EUROPE STEM CELL TRANSPLANT IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION) 151
  • TABLE 136 EUROPE SURGICAL TREATMENT IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION) 151
  • TABLE 137 EUROPE HUNTER SYNDROME TREATMENT MARKET, BY COMPLICATIONS, 2019-2028 (USD MILLION) 152
  • TABLE 138 EUROPE HUNTER SYNDROME TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION) 152
  • TABLE 139 EUROPE HUNTER SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION) 152
  • TABLE 140 GERMANY HUNTER SYNDROME TREATMENT MARKET, BY SEVERITY, 2019-2028 (USD MILLION) 153
  • TABLE 141 GERMANY HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION) 153
  • TABLE 142 GERMANY ENZYME REPLACEMENT THERAPY (ERT) IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION) 153
  • TABLE 143 GERMANY STEM CELL TRANSPLANT IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION) 153
  • TABLE 144 GERMANY SURGICAL TREATMENT IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION) 153
  • TABLE 145 GERMANY HUNTER SYNDROME TREATMENT MARKET, BY COMPLICATIONS, 2019-2028 (USD MILLION) 154
  • TABLE 146 GERMANY HUNTER SYNDROME TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION) 154
  • TABLE 147 GERMANY HUNTER SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION) 154
  • TABLE 148 FRANCE HUNTER SYNDROME TREATMENT MARKET, BY SEVERITY, 2019-2028 (USD MILLION) 156
  • TABLE 149 FRANCE HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION) 156
  • TABLE 150 FRANCE ENZYME REPLACEMENT THERAPY (ERT) IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION) 156
  • TABLE 151 FRANCE STEM CELL TRANSPLANT IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION) 156
  • TABLE 152 FRANCE SURGICAL TREATMENT IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION) 157
  • TABLE 153 FRANCE HUNTER SYNDROME TREATMENT MARKET, BY COMPLICATIONS, 2019-2028 (USD MILLION) 157
  • TABLE 154 FRANCE HUNTER SYNDROME TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION) 157
  • TABLE 155 FRANCE HUNTER SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION) 158
  • TABLE 156 U.K. HUNTER SYNDROME TREATMENT MARKET, BY SEVERITY, 2019-2028 (USD MILLION) 159
  • TABLE 157 U.K. HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION) 159
  • TABLE 158 U.K. ENZYME REPLACEMENT THERAPY (ERT) IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION) 159
  • TABLE 159 U.K. STEM CELL TRANSPLANT IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION) 159
  • TABLE 160 U.K. SURGICAL TREATMENT IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION) 160
  • TABLE 161 U.K. HUNTER SYNDROME TREATMENT MARKET, BY COMPLICATIONS, 2019-2028 (USD MILLION) 160
  • TABLE 162 U.K. HUNTER SYNDROME TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION) 160
  • TABLE 163 U.K. HUNTER SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION) 161
  • TABLE 164 ITALY HUNTER SYNDROME TREATMENT MARKET, BY SEVERITY, 2019-2028 (USD MILLION) 162
  • TABLE 165 ITALY HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION) 162
  • TABLE 166 ITALY ENZYME REPLACEMENT THERAPY (ERT) IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION) 162
  • TABLE 167 ITALY STEM CELL TRANSPLANT IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION) 162
  • TABLE 168 ITALY SURGICAL TREATMENT IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION) 163
  • TABLE 169 ITALY HUNTER SYNDROME TREATMENT MARKET, BY COMPLICATIONS, 2019-2028 (USD MILLION) 163
  • TABLE 170 ITALY HUNTER SYNDROME TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION) 163
  • TABLE 171 ITALY HUNTER SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION) 164
  • TABLE 172 SPAIN HUNTER SYNDROME TREATMENT MARKET, BY SEVERITY, 2019-2028 (USD MILLION) 165
  • TABLE 173 SPAIN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION) 165
  • TABLE 174 SPAIN ENZYME REPLACEMENT THERAPY (ERT) IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION) 165
  • TABLE 175 SPAIN STEM CELL TRANSPLANT IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION) 165
  • TABLE 176 SPAIN SURGICAL TREATMENT IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION) 166
  • TABLE 177 SPAIN HUNTER SYNDROME TREATMENT MARKET, BY COMPLICATIONS, 2019-2028 (USD MILLION) 166
  • TABLE 178 SPAIN HUNTER SYNDROME TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION) 166
  • TABLE 179 SPAIN HUNTER SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION) 167
  • TABLE 180 NETHERLANDS HUNTER SYNDROME TREATMENT MARKET, BY SEVERITY, 2019-2028 (USD MILLION) 168
  • TABLE 181 NETHERLANDS HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION) 168
  • TABLE 182 NETHERLANDS ENZYME REPLACEMENT THERAPY (ERT) IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION) 168
  • TABLE 183 NETHERLANDS STEM CELL TRANSPLANT IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION) 168
  • TABLE 184 NETHERLANDS SURGICAL TREATMENT IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION) 169
  • TABLE 185 NETHERLANDS HUNTER SYNDROME TREATMENT MARKET, BY COMPLICATIONS, 2019-2028 (USD MILLION) 169
  • TABLE 186 NETHERLANDS HUNTER SYNDROME TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION) 169
  • TABLE 187 NETHERLANDS HUNTER SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION) 170
  • TABLE 188 RUSSIA HUNTER SYNDROME TREATMENT MARKET, BY SEVERITY, 2019-2028 (USD MILLION) 171
  • TABLE 189 RUSSIA HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION) 171
  • TABLE 190 RUSSIA ENZYME REPLACEMENT THERAPY (ERT) IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION) 171
  • TABLE 191 RUSSIA STEM CELL TRANSPLANT IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION) 171
  • TABLE 192 RUSSIA SURGICAL TREATMENT IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION) 172
  • TABLE 193 RUSSIA HUNTER SYNDROME TREATMENT MARKET, BY COMPLICATIONS, 2019-2028 (USD MILLION) 172
  • TABLE 194 RUSSIA HUNTER SYNDROME TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION) 172
  • TABLE 195 RUSSIA HUNTER SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION) 173
  • TABLE 196 SWITZERLAND HUNTER SYNDROME TREATMENT MARKET, BY SEVERITY, 2019-2028 (USD MILLION) 174
  • TABLE 197 SWITZERLAND HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION) 174
  • TABLE 198 SWITZERLAND ENZYME REPLACEMENT THERAPY (ERT) IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION) 174
  • TABLE 199 SWITZERLAND STEM CELL TRANSPLANT IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION) 174
  • TABLE 200 SWITZERLAND SURGICAL TREATMENT IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION) 175
  • TABLE 201 SWITZERLAND HUNTER SYNDROME TREATMENT MARKET, BY COMPLICATIONS, 2019-2028 (USD MILLION) 175
  • TABLE 202 SWITZERLAND HUNTER SYNDROME TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION) 175
  • TABLE 203 SWITZERLAND HUNTER SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION) 176
  • TABLE 204 TURKEY HUNTER SYNDROME TREATMENT MARKET, BY SEVERITY, 2019-2028 (USD MILLION) 177
  • TABLE 205 TURKEY HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION) 177
  • TABLE 206 TURKEY ENZYME REPLACEMENT THERAPY (ERT) IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION) 177
  • TABLE 207 TURKEY STEM CELL TRANSPLANT IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION) 177
  • TABLE 208 TURKEY SURGICAL TREATMENT IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION) 178
  • TABLE 209 TURKEY HUNTER SYNDROME TREATMENT MARKET, BY COMPLICATIONS, 2019-2028 (USD MILLION) 178
  • TABLE 210 TURKEY HUNTER SYNDROME TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION) 178
  • TABLE 211 TURKEY HUNTER SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION) 179
  • TABLE 212 AUSTRIA HUNTER SYNDROME TREATMENT MARKET, BY SEVERITY, 2019-2028 (USD MILLION) 180
  • TABLE 213 AUSTRIA HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION) 180
  • TABLE 214 AUSTRIA ENZYME REPLACEMENT THERAPY (ERT) IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION) 180
  • TABLE 215 AUSTRIA STEM CELL TRANSPLANT IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION) 180
  • TABLE 216 AUSTRIA SURGICAL TREATMENT IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION) 181
  • TABLE 217 AUSTRIA HUNTER SYNDROME TREATMENT MARKET, BY COMPLICATIONS, 2019-2028 (USD MILLION) 181
  • TABLE 218 AUSTRIA HUNTER SYNDROME TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION) 181
  • TABLE 219 AUSTRIA HUNTER SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION) 182
  • TABLE 220 NORWAY HUNTER SYNDROME TREATMENT MARKET, BY SEVERITY, 2019-2028 (USD MILLION) 183
  • TABLE 221 NORWAY HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION) 183
  • TABLE 222 NORWAY ENZYME REPLACEMENT THERAPY (ERT) IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION) 183
  • TABLE 223 NORWAY STEM CELL TRANSPLANT IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION) 183
  • TABLE 224 NORWAY SURGICAL TREATMENT IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION) 184
  • TABLE 225 NORWAY HUNTER SYNDROME TREATMENT MARKET, BY COMPLICATIONS, 2019-2028 (USD MILLION) 184
  • TABLE 226 NORWAY HUNTER SYNDROME TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION) 184
  • TABLE 227 NORWAY HUNTER SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION) 185
  • TABLE 228 HUNGARY HUNTER SYNDROME TREATMENT MARKET, BY SEVERITY, 2019-2028 (USD MILLION) 186
  • TABLE 229 HUNGARY HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION) 186
  • TABLE 230 HUNGARY ENZYME REPLACEMENT THERAPY (ERT) IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION) 186
  • TABLE 231 HUNGARY STEM CELL TRANSPLANT IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION) 186
  • TABLE 232 HUNGARY SURGICAL TREATMENT IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION) 186
  • TABLE 233 HUNGARY HUNTER SYNDROME TREATMENT MARKET, BY COMPLICATIONS, 2019-2028 (USD MILLION) 187
  • TABLE 234 HUNGARY HUNTER SYNDROME TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION) 187
  • TABLE 235 HUNGARY HUNTER SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION) 187
  • TABLE 236 LITHUANIA HUNTER SYNDROME TREATMENT MARKET, BY SEVERITY, 2019-2028 (USD MILLION) 189
  • TABLE 237 LITHUANIA HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION) 189
  • TABLE 238 LITHUANIA ENZYME REPLACEMENT THERAPY (ERT) IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION) 189
  • TABLE 239 LITHUANIA STEM CELL TRANSPLANT IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION) 189
  • TABLE 240 LITHUANIA SURGICAL TREATMENT IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION) 190
  • TABLE 241 LITHUANIA HUNTER SYNDROME TREATMENT MARKET, BY COMPLICATIONS, 2019-2028 (USD MILLION) 190
  • TABLE 242 LITHUANIA HUNTER SYNDROME TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION) 190
  • TABLE 243 LITHUANIA HUNTER SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION) 191
  • TABLE 244 POLAND HUNTER SYNDROME TREATMENT MARKET, BY SEVERITY, 2019-2028 (USD MILLION) 192
  • TABLE 245 POLAND HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION) 192
  • TABLE 246 POLAND ENZYME REPLACEMENT THERAPY (ERT) IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION) 192
  • TABLE 247 POLAND STEM CELL TRANSPLANT IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION) 192
  • TABLE 248 POLAND SURGICAL TREATMENT IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION) 193
  • TABLE 249 POLAND HUNTER SYNDROME TREATMENT MARKET, BY COMPLICATIONS, 2019-2028 (USD MILLION) 193
  • TABLE 250 POLAND HUNTER SYNDROME TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION) 193
  • TABLE 251 POLAND HUNTER SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION) 194
  • TABLE 252 IRELAND HUNTER SYNDROME TREATMENT MARKET, BY SEVERITY, 2019-2028 (USD MILLION) 195
  • TABLE 253 IRELAND HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION) 195
  • TABLE 254 IRELAND ENZYME REPLACEMENT THERAPY (ERT) IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION) 195
  • TABLE 255 IRELAND STEM CELL TRANSPLANT IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION) 195
  • TABLE 256 IRELAND SURGICAL TREATMENT IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION) 196
  • TABLE 257 IRELAND HUNTER SYNDROME TREATMENT MARKET, BY COMPLICATIONS, 2019-2028 (USD MILLION) 196
  • TABLE 258 IRELAND HUNTER SYNDROME TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION) 196
  • TABLE 259 IRELAND HUNTER SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION) 197
  • TABLE 260 REST OF EUROPE HUNTER SYNDROME TREATMENT MARKET, BY SEVERITY, 2019-2028 (USD MILLION) 198
  • TABLE 261 MIDDLE EAST & AFRICA HUNTER SYNDROME TREATMENT MARKET, BY COUNTRY, 2019-2028 (USD MILLION) 202
  • TABLE 262 MIDDLE EAST & AFRICA HUNTER SYNDROME TREATMENT MARKET, BY SEVERITY, 2019-2028 (USD MILLION) 202
  • TABLE 263 MIDDLE EAST & AFRICA HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION) 202
  • TABLE 264 MIDDLE EAST & AFRICA ENZYME REPLACEMENT THERAPY (ERT) IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION) 203
  • TABLE 265 MIDDLE EAST & AFRICA STEM CELL TRANSPLANT IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION) 203

LIST OF FIGURES

  • FIGURE 1 GLOBAL HUNTER SYNDROME TREATMENT MARKET : SEGMENTATION 37
  • FIGURE 2 GLOBAL HUNTER SYNDROME TREATMENT MARKET : DATA TRIANGULATION 40
  • FIGURE 3 GLOBAL HUNTER SYNDROME TREATMENT MARKET : DROC ANALYSIS 41
  • FIGURE 4 GLOBAL HUNTER SYNDROME TREATMENT MARKET : GLOBAL VS REGIONAL MARKET ANALYSIS 42
  • FIGURE 5 GLOBAL HUNTER SYNDROME TREATMENT MARKET : COMPANY RESEARCH ANALYSIS 42
  • FIGURE 6 GLOBAL HUNTER SYNDROME TREATMENT MARKET : INTERVIEW DEMOGRAPHICS 45
  • FIGURE 7 GLOBAL HUNTER SYNDROME TREATMENT MARKET : DBMR MARKET POSITION GRID 46
  • FIGURE 8 GLOBAL HUNTER SYNDROME TREATMENT MARKET : MARKET END USER COVERAGE GRID 47
  • FIGURE 9 GLOBAL HUNTER SYNDROME TREATMENT MARKET : VENDOR SHARE ANALYSIS 48
  • FIGURE 10 GLOBAL HUNTER SYNDROME TREATMENT MARKET : SEGMENTATION 53
  • FIGURE 11 INCREASING PREVALANCE OF HUNTER SYNDROME IS EXPECTED TO DRIVE THE GLOBAL HUNTER SYNDROME TREATMENT MARKET IN THE FORECAST PERIOD OF 2021 TO 2028 54
  • FIGURE 12 MODERATE TO SEVERE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL HUNTER SYNDROME TREATMENT MARKET IN 2021 & 2028 54
  • FIGURE 13 NORTH AMERICA IS EXPECTED TO DOMINATE THE GLOBAL HUNTER SYNDROME TREATMENT MARKET AND IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2021 TO 2028 55
  • FIGURE 14 NORTH AMERICA IS THE FASTEST GROWING MARKET FOR HUNTER SYNDROME TREATMENT PRODUCT MANUFACTURERS IN THE FORECAST PERIOD OF 2021 TO 2028 56
  • FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF GLOBAL HUNTER SYNDROME TREATMENT MARKET 65
  • FIGURE 16 GLOBAL HUNTER SYNDROME TREATMENT MARKET: BY SEVERITY, 2020 77
  • FIGURE 19 GLOBAL HUNTER SYNDROME TREATMENT MARKET: BY END USER, 2020 93
  • FIGURE 20 GLOBAL HUNTER SYNDROME TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2020 97
  • FIGURE 21 GLOBAL HUNTER SYNDROME TREATMENT MARKET: SNAPSHOT (2020) 102
  • FIGURE 22 GLOBAL HUNTER SYNDROME TREATMENT MARKET: BY REGION (2020) 103
  • FIGURE 23 GLOBAL HUNTER SYNDROME TREATMENT MARKET: BY REGION (2021 & 2028) 103
  • FIGURE 24 GLOBAL HUNTER SYNDROME TREATMENT MARKET: BY REGION (2020 & 2028) 104
  • FIGURE 25 GLOBAL HUNTER SYNDROME TREATMENT MARKET: BY SEVERITY (2021-2028) 104
  • FIGURE 26 ASIA-PACIFIC HUNTER SYNDROME TREATMENT MARKET: SNAPSHOT (2020) 106
  • FIGURE 27 ASIA-PACIFIC HUNTER SYNDROME TREATMENT MARKET: BY COUNTRY (2020) 107
  • FIGURE 28 ASIA-PACIFIC HUNTER SYNDROME TREATMENT MARKET: BY COUNTRY (2021 & 2028) 107
  • FIGURE 29 ASIA-PACIFIC HUNTER SYNDROME TREATMENT MARKET: BY COUNTRY (2020 & 2028) 108
  • FIGURE 30 ASIA-PACIFIC HUNTER SYNDROME TREATMENT MARKET: BY SEVERITY (2021-2028) 108
  • FIGURE 31 EUROPE HUNTER SYNDROME TREATMENT MARKET: SNAPSHOT (2020) 146
  • FIGURE 32 EUROPE HUNTER SYNDROME TREATMENT MARKET: BY COUNTRY (2020) 148
  • FIGURE 33 EUROPE HUNTER SYNDROME TREATMENT MARKET: BY COUNTRY (2021 & 2028) 148
  • FIGURE 34 EUROPE HUNTER SYNDROME TREATMENT MARKET: BY COUNTRY (2020 & 2028) 149
  • FIGURE 35 EUROPE HUNTER SYNDROME TREATMENT MARKET: BY SEVERITY (2021-2028) 149
  • FIGURE 36 MIDDLE EAST & AFRICA HUNTER SYNDROME TREATMENT MARKET: SNAPSHOT (2020) 199
  • FIGURE 37 MIDDLE EAST & AFRICA HUNTER SYNDROME TREATMENT MARKET: BY COUNTRY (2020) 200
  • FIGURE 38 MIDDLE EAST & AFRICA HUNTER SYNDROME TREATMENT MARKET: BY COUNTRY (2021 & 2028) 200
  • FIGURE 39 MIDDLE EAST & AFRICA HUNTER SYNDROME TREATMENT MARKET: BY COUNTRY (2020 & 2028) 201
  • FIGURE 40 MIDDLE EAST & AFRICA HUNTER SYNDROME TREATMENT MARKET: BY SEVERITY (2021-2028) 201
  • FIGURE 41 NORTH AMERICA HUNTER SYNDROME TREATMENT MARKET: SNAPSHOT (2020) 224
  • FIGURE 42 NORTH AMERICA HUNTER SYNDROME TREATMENT MARKET: BY COUNTRY (2020) 225
  • FIGURE 43 NORTH AMERICA HUNTER SYNDROME TREATMENT MARKET: BY COUNTRY (2021 & 2028) 225
  • FIGURE 44 NORTH AMERICA HUNTER SYNDROME TREATMENT MARKET: BY COUNTRY (2020 & 2028) 226
  • FIGURE 45 NORTH AMERICA HUNTER SYNDROME TREATMENT MARKET: BY SEVERITY (2021-2028) 226
  • FIGURE 46 SOUTH AMERICA HUNTER SYNDROME TREATMENT MARKET: SNAPSHOT (2020) 239
  • FIGURE 47 SOUTH AMERICA HUNTER SYNDROME TREATMENT MARKET: BY COUNTRY (2020) 240
  • FIGURE 48 SOUTH AMERICA HUNTER SYNDROME TREATMENT MARKET: BY COUNTRY (2021 & 2028) 240
  • FIGURE 49 SOUTH AMERICA HUNTER SYNDROME TREATMENT MARKET: BY COUNTRY (2020 & 2028) 241
  • FIGURE 50 SOUTH AMERICA HUNTER SYNDROME TREATMENT MARKET: BY SEVERITY (2021-2028) 241
  • FIGURE 51 GLOBAL HUNTER SYNDROME TREATMENT MARKET: COMPANY SHARE 2020 (%) 255
  • FIGURE 52 NORTH AMERICA HUNTER SYNDROME TREATMENT MARKET: COMPANY SHARE 2020 (%) 256
  • FIGURE 53 EUROPE HUNTER SYNDROME TREATMENT MARKET: COMPANY SHARE 2020 (%) 257
  • FIGURE 54 ASIA-PACIFIC HUNTER SYNDROME TREATMENT MARKET: COMPANY SHARE 2020 (%) 258